CY1118179T1 - Φαρμακευτικη συνθεση - Google Patents

Φαρμακευτικη συνθεση

Info

Publication number
CY1118179T1
CY1118179T1 CY20161101115T CY161101115T CY1118179T1 CY 1118179 T1 CY1118179 T1 CY 1118179T1 CY 20161101115 T CY20161101115 T CY 20161101115T CY 161101115 T CY161101115 T CY 161101115T CY 1118179 T1 CY1118179 T1 CY 1118179T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
diosylates
quinazolineamines
treatment
methods
Prior art date
Application number
CY20161101115T
Other languages
English (en)
Inventor
Barry Howard Carter
Dwayne A Campbell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115487&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118179(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1118179T1 publication Critical patent/CY1118179T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Περιγράφονται φαρμακευτικές συνθέσεις που προορίζονται για χορήγηση από το στόμα που περιέχουν διτοσυλικά άλατα 4-κιναζολινεαμίνων καθώς και οι μέθοδοι για τη χρήση αυτών στη θεραπεία διαταραχών που χαρακτηρίζονται από παρεκκλίνουσα δραστηριότητα ΡΤΚ της οικογένειας erbB.
CY20161101115T 2005-04-19 2016-11-03 Φαρμακευτικη συνθεση CY1118179T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67280505P 2005-04-19 2005-04-19
PCT/US2006/014447 WO2006113649A1 (en) 2005-04-19 2006-04-18 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CY1118179T1 true CY1118179T1 (el) 2017-06-28

Family

ID=37115487

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101115T CY1118179T1 (el) 2005-04-19 2016-11-03 Φαρμακευτικη συνθεση

Country Status (28)

Country Link
US (3) US8821927B2 (el)
EP (1) EP1871347B1 (el)
JP (1) JP5202302B2 (el)
KR (1) KR101356748B1 (el)
CN (1) CN101203211B (el)
AR (1) AR054252A1 (el)
AU (1) AU2006236423B2 (el)
BR (1) BRPI0609962B1 (el)
CA (1) CA2606207C (el)
CY (1) CY1118179T1 (el)
DK (1) DK1871347T3 (el)
EA (1) EA200702253A1 (el)
ES (1) ES2601503T3 (el)
HR (1) HRP20161429T1 (el)
HU (1) HUE030982T2 (el)
IL (1) IL186336A0 (el)
LT (1) LT1871347T (el)
MA (1) MA29404B1 (el)
MX (1) MX2007013089A (el)
NO (1) NO20075111L (el)
NZ (1) NZ562223A (el)
PE (1) PE20061430A1 (el)
PL (1) PL1871347T3 (el)
PT (1) PT1871347T (el)
SI (1) SI1871347T1 (el)
TW (1) TW200716204A (el)
WO (1) WO2006113649A1 (el)
ZA (1) ZA200708705B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200716204A (en) * 2005-04-19 2007-05-01 Smithkline Beecham Cork Ltd Pharmaceutical composition
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2158912A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010099150A1 (en) * 2009-02-24 2010-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical tablet and process
US20120245351A1 (en) * 2009-09-29 2012-09-27 Natco Pharma Limited Process for the preparation of lapatinib and its pharmaceutically acceptable salts
WO2011146710A1 (en) 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination
US9180129B2 (en) 2010-05-21 2015-11-10 Novartis Ag Combination of lapatinib and trametinib
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AU2011285928B9 (en) 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
WO2014128107A1 (en) 2013-02-19 2014-08-28 Hexal Ag Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
CN106389373B (zh) * 2015-07-29 2019-07-02 四川科伦药物研究院有限公司 一种二甲苯磺酸拉帕替尼片剂及其制备方法
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法
IL310527A (en) 2015-10-23 2024-03-01 B3Ar Therapeutics Inc Zwitterion solvegron and its uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
CA2288140C (en) 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CN1305872C (zh) 2000-06-30 2007-03-21 葛兰素集团有限公司 喹唑啉类化合物的制备方法
AU2002236765A1 (en) 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
US20050176740A1 (en) 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
EP1810034A4 (en) 2002-06-19 2008-06-25 Smithkline Beecham Corp PREDICTIVE MARKERS IN CANCER THERAPY
TW200716204A (en) * 2005-04-19 2007-05-01 Smithkline Beecham Cork Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
DK1871347T3 (en) 2016-11-28
BRPI0609962A2 (pt) 2011-10-11
CA2606207C (en) 2014-11-18
HRP20161429T1 (hr) 2016-12-16
EP1871347A4 (en) 2012-10-31
JP2008536931A (ja) 2008-09-11
PL1871347T3 (pl) 2017-04-28
PT1871347T (pt) 2016-11-10
US20080206330A1 (en) 2008-08-28
US20140335177A1 (en) 2014-11-13
KR101356748B1 (ko) 2014-02-06
IL186336A0 (en) 2008-01-20
EP1871347A1 (en) 2008-01-02
US8821927B2 (en) 2014-09-02
CA2606207A1 (en) 2006-10-26
JP5202302B2 (ja) 2013-06-05
LT1871347T (lt) 2016-11-10
ES2601503T3 (es) 2017-02-15
MA29404B1 (fr) 2008-04-01
SI1871347T1 (sl) 2016-11-30
CN101203211A (zh) 2008-06-18
NZ562223A (en) 2010-01-29
PE20061430A1 (es) 2007-01-25
AU2006236423B2 (en) 2009-12-10
HUE030982T2 (en) 2017-06-28
AU2006236423A1 (en) 2006-10-26
EA200702253A1 (ru) 2008-04-28
AR054252A1 (es) 2007-06-13
MX2007013089A (es) 2008-01-14
KR20080005557A (ko) 2008-01-14
NO20075111L (no) 2007-11-16
CN101203211B (zh) 2012-08-08
BRPI0609962B1 (pt) 2022-01-18
EP1871347B1 (en) 2016-08-03
WO2006113649A1 (en) 2006-10-26
ZA200708705B (en) 2009-12-30
US20160143909A1 (en) 2016-05-26
TW200716204A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
CY1118179T1 (el) Φαρμακευτικη συνθεση
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
CY1111458T1 (el) Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
ATE484494T1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
SE0401342D0 (sv) Therapeutic compounds
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
SE0203817D0 (sv) New composition
CY1108865T1 (el) Υποκατεστημενες 2,5-διαμινομευθυλο-1η-πυρρολες
DE60321954D1 (de) Synergistische zusammensetzung enthaltend roflumilast und (r,r)-formoterol